OVERVIEW: What every practitioner needs to know
Are you sure your patient has hyphema? What are the typical findings for this disease?
Patients have a history of ocular trauma. Older patients may complain of blurred vision.
Blood in the anterior chamber (hyphema) may range from microhyphema, with red blood cells visible only by slit-lamp examination to layered blood in the anterior chamber to the entire anterior chamber filled with blood. Larger amounts of bleeding often result in layering of red blood cells in a gravity-dependent manner. In an upright patient, the blood layers inferiorly (
Figure 1). A supine patient may have the blood layer over the pupil and lens. If the entire anterior chamber is filled with blood it may be red or black. A black hyphema is called a blackball or eightball hyphema (Figure 2).
What other disease/condition shares some of these symptoms?
Nonaccidental trauma (child abuse) must be a consideration in any child with ocular injuries not consistent with the history provided. Bleeding diatheses from leukemia, blood dyscrasias, and clotting disorders as well as juvenile xanthogranuloma and retinoblastoma can produce spontaneous hyphema in childhood. Other causes include iris neovascularization, previous intraocular surgery, and herpes simplex and herpes zoster iridocyclitis.Note: Retinoblastoma must always be ruled out in a child with nontraumatic bleeding. This may require ultrasonography or selective evaluation with computed tomography (CT) or magnetic resonance imaging if hyphema blocks the view into posterior segments of the eye.
What caused this disease to develop at this time?
Blunt trauma to the globe is the principal cause of hyphema. Compression of the globe with expansion/flattening in the equatorial zone causes tearing of anterior chamber vessels.
Surgery for cataracts or glaucoma can cause spontaneous hemorrhage with hyphema formation.
There are a number of nontraumatic conditions that cause spontaneous hyphema. Juvenile xanthogranuloma, retinoblastoma, leukemia, blood dyscrasias and coagulopathies, neovascularization of the iris, ciliary body melanoma, herpes simplex, zoster iridocyclitis, and iris microaneurysm are the major considerations.
What laboratory studies should you request to help confirm the diagnosis? How should you interpret the results?
Hyphema is a clinical diagnosis. Patients with possible sickle cell disease (African American and Mediterranean patients in particular) need to be screened for sickle cell disease or trait.
Would imaging studies be helpful? If so, which ones?
Ultrasonographic biomicroscopy or CT of the orbits and brain may be indicated when there is a poor view of the intraocular contents with possible disruption of the globe or possibility of an intraocular foreign body or orbital fractures.
If you are able to confirm that the patient has this disease, what treatment should be initiated?
Once the diagnosis of hyphema is confirmed, the mechanism of injury as well as the physical examination will assist in determining whether there are serious associated injuries to the globe, orbit, and surrounding tissues (Figure 3). Protection of the eye from further injury during the examination or during ancillary testing, such as CT, must be a priority. A metal or plastic shield, not an eye patch, must protect the eye at all times.
Certain aspects of hyphema treatment remain controversial. The mainstream considerations are the following:
Activity should be limited to bed rest with bathroom privileges. This is permissible as home care in compliant patients. Noncompliant patients, younger children, and those in whom abuse is suspected, as well as patients with severe associated injuries or significant intraocular concerns should be hospitalized.
The head of the bed should be elevated approximately 30 degrees.
Nonsteroidal antiinflammatory drugs and aspirin products may not be used. Acetaminophen or mild analgesic agents should be used.
Longer acting dilating compounds such as atropine 1% or scopolamine 0.25% should be used.
The topical steroid, prednisolone 1%, is used with caution. Children have a risk of cataract formation or intraocular pressure elevation from steroid treatment.
Elevated intraocular pressure may require specific therapy. This should be performed by an ophthalmologist.
Patients should be evaluated daily for at least 3 days and possibly 5-7 days depending on the condition. Rebleeding is a potentially serious complication that is most likely to occur between 2 and 5 days after the initial injury. The rebleeding rate has varied according to different studies. The consensus appears to be that this incidence is less than 5%. In patients in whom rebleeding occurs, approximately 50% will experience glaucoma and vision-threatening complications.
Patients with hyphema should be reevaluated approximately 1 month after the injury for a complete anterior and posterior segment evaluation. Consideration for a yearly examination is reasonable because hyphema injury results in a theoretical lifelong risk for glaucoma.
Antifibrinolytic agents to reduce the incidence of rebleeding have been used with efficacy.There have been significant side effects, such as nausea, postural hypotension, and vomiting, which strongly suggests that patients using these agents should be hospitalized. This therapy is less frequently used because of these considerations. A topical aminocaproic acid is under development. This shoud have fewer systemic considerations such as nausea and hypotension, but further research is needed before it can be released as a treatment modality for hyphema.
What are the adverse effects associated with each treatment option?
What are the possible outcomes of hyphema?
Hyphema is a potentially vision-threatening condition. Any size hyphema can bleed again. The goal is to prevent rebleeding, control the intraocular pressure, and recognize associated conditions such as significant injury to the iris, cataract, and retina. Children are at risk for amblyopia and must be closely monitored as the hyphema resolves. Amblyopia therapy must be quickly instituted when discovered.
What causes this disease and how frequent is it?
Traumatic hyphema is more likely to be found in young male patients
What complications might you expect from the disease or treatment of the disease?
Traumatic hyphema can be associated with injury to any structure of the eye from lid to the optic nerve.
Most traumatic hyphemas resolve without loss of vision or development of glaucoma.The rate for rebleeding is approximately 5%, with increased intraocular pressure developing in approximately 50% of these patients. Steroid drop therapy can also elevate the pressure. The pressure increase can produce corneal blood staining and optic atrophy, with permanent loss of vision.
Amblyopia is an additional concern in children. Temporary occlusion of the visual axis from blood, corneal edema, or even the protective shield can produce amblyopia.
How can this disease be prevented?
Protection from avoidable injury would significantly reduce the rate of hyphema occurrence. Eye protection for work and play is necessary for both children and adults.
What is the evidence?
Ehlers, JP, Chirag, PS. “Hyphema and microhyphema”. 2008. (This is the "on-the-job" reference source for management of hyphema. This updated synopsis of clinical practice provides recognized methods for therapy with rare comment on less-established therapies.)
Gharaibeh, A, Savage, HI, Scherer, RW. “Medical interventions for traumatic hyphema (review)”. The Cochrane Library. 2011. (This is an exhaustive review of the hyphema literature. The authors conclude that taking into consideration the risks of side effects of antifibrinolytic agents, corticosteroids, and cycloplegic agents, "it might be reasonable to recommend their usage only in those patients with high risk of complications." They also found "no convincing evidence of benefit to binocular patching over monocular patching, bed rest over moderate activity, or elevation of the head in a semireclined position in the treatment of traumatic hyphema." Compelling scientific evidence may not be available for many clincally accepted practice modalities.)
Ongoing controversies regarding etiology, diagnosis, treatment
Controversies regarding hyphema management have resulted in discussions regarding optimal therapy.
Topical steroid and/or (versus) oral steroid application is one consideration.
Antifibrinolytic agents have been less widely accepted because of the nausea, hypotension, and vomiting complications from them. This frequently necessitates antiemetic therapy and consideration of hospitalization in patients who might otherwise be managed successfully as outpatients.
Hospitalization with sedation and bilateral patching was advocated at one time for pediatric patients. Generally speaking, hospitalization is rarely indicated except for the most noncompliant patients/undependable families, or severely injured children.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- OVERVIEW: What every practitioner needs to know
- Are you sure your patient has hyphema? What are the typical findings for this disease?
- What other disease/condition shares some of these symptoms?
- What caused this disease to develop at this time?
- What laboratory studies should you request to help confirm the diagnosis? How should you interpret the results?
- Would imaging studies be helpful? If so, which ones?
- If you are able to confirm that the patient has this disease, what treatment should be initiated?
- What are the adverse effects associated with each treatment option?
- What are the possible outcomes of hyphema?
- What causes this disease and how frequent is it?
- What complications might you expect from the disease or treatment of the disease?
- How can this disease be prevented?
- What is the evidence?
- Ongoing controversies regarding etiology, diagnosis, treatment